Nationwide cohort study reveals less favorable survival in advanced endometrial cancer with dostarlimab and chemotherapy, indicating key safety insights.
This first real-world study of dostarlimab plus chemotherapy in advanced or recurrent endometrial cancer involved an older, more comorbid, and less selected population with more advanced disease than in RUBY. Survival outcomes were less favorable, but the safety profile was comparable.
No takes yet. Share an insight, caveat, or question.
Singier et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: